EX-99.1(B)4 11 dex991b4.htm CONSOLIDATED STATEMENTS OF CASH FLOW Prepared by R.R. Donnelley Financial -- Consolidated Statements of Cash Flow
 
Exhibit 99.1 (b) 4
 
TechRx Incorporated
 
Consolidated Statements of Cash Flows
 
    
Eleven Months Ended May 31 2002

    
Year ended June 30 2001

 
    
(Dollars in Thousands)
 
Operating activities
                 
Net loss
  
$
(13,764
)
  
$
(26,527
)
Adjustments to reconcile net loss to net cash provided (used) by operating activities:
                 
Depreciation and amortization
  
 
7,330
 
  
 
11,166
 
Impairment of assets
  
 
—  
 
  
 
7,102
 
Other noncash charges
  
 
—  
 
  
 
174
 
Stock compensation expense
  
 
696
 
  
 
—  
 
Working capital items:
                 
Accounts receivable (including NDCHealth)
  
 
(1,100
)
  
 
2,985
 
Prepaid expenses and other
  
 
(205
)
  
 
378
 
Accounts payable (including NDCHealth)
  
 
(86
)
  
 
3,784
 
Accrued expenses
  
 
(1,448
)
  
 
4,136
 
Deferred revenues
  
 
(551
)
  
 
(3,165
)
Accrued restructuring
  
 
121
 
  
 
1,980
 
    


  


Net cash (used) provided by operating activities
  
 
(9,007
)
  
 
2,013
 
Investing activities
                 
Acquisitions (including NDC Pharmacy Systems)
  
 
—  
 
  
 
(28,206
)
Purchase of furniture, fixtures, and equipment
  
 
(2,458
)
  
 
(3,044
)
Capitalized software
  
 
(6,401
)
  
 
—  
 
    


  


Net cash used by investing activities
  
 
(8,859
)
  
 
(31,250
)
Financing activities
                 
Repayment of long-term obligations (including NDCHealth)
  
 
(8,302
)
  
 
(5,895
)
Proceeds from borrowings
  
 
11,906
 
  
 
5,534
 
Proceeds from stock issuance activities—net
  
 
10,170
 
  
 
37,410
 
Other
  
 
(72
)
  
 
(38
)
    


  


Net cash provided by financing activities
  
 
13,702
 
  
 
37,011
 
    


  


Net (decrease) increase in cash
  
 
(4,164
)
  
 
7,774
 
Cash—beginning of year
  
 
11,513
 
  
 
3,739
 
    


  


Cash—end of year
  
$
7,349
 
  
$
11,513
 
    


  


 
See accompanying notes.